{"analyses":[{"ciLowerLimit":"0.986","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.037","estimateComment":"95% CI for the odds ratio adjusted for sokal risk group and region are based on Mantel-Haenszel confidence limits.","groupDescription":"If the primary analysis was significant, each member of the short-term family (CCyR by Month 12, MMR by Month 18) was tested via Bonferroni's procedure at the 1-sided level of 0.0125.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0303","pValueComment":"1-sided p-value based on CMH test for general association between treatment and response with stratification by sokal risk group (low, intermediate, high) and region (1-3) at time of randomization. Statistical significance threshold: 1-sided 0.0125.","paramType":"Odds Ratio (OR)","paramValue":"1.418","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.9","upperLimit":"67.1","value":"61.0"},{"groupId":"OG001","lowerLimit":"46.4","upperLimit":"59.0","value":"52.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"246"},{"groupId":"OG001","value":"241"}],"units":"Participants"}],"description":"MMR was defined as a ratio of BCR-ABL/ABL \\<=0.1% on the international scale (\\>=3 log reduction from standardized baseline in ratio of BCR-ABL to ABL transcripts \\[\\>=3000 ABL required\\]) by quantitative RT-qPCR. The percentage of participants with MMR for up to Month 18 are reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Philadelphia chromosome-positive CML received bosutinib tablets at a dose of 400 mg, orally once daily in the core treatment phase of 12 months and continued the same treatment into the extension phase or followed up for safety for up to approximately 4 years, until the end of the study, treatment failure, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first.","id":"OG000","title":"Bosutinib"},{"description":"Participants with Philadelphia chromosome-positive CML received imatinib tablets at a dose of 400 mg, orally once daily in the core treatment phase of 12 months and continued the same treatment into the extension phase or followed up for safety for up to approximately 4 years, until the end of the study, treatment failure, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first.","id":"OG001","title":"Imatinib"}],"paramType":"NUMBER","populationDescription":"mITT population included all randomized participants with Ph+ CML harboring the b2a2 and/or b3a2 transcript and baseline BCR-ABL copies \\>0 with study drug assignment designated according to initial randomization.","reportingStatus":"POSTED","timeFrame":"Up to Month 18","title":"Percentage of Participants With Major Molecular Response (MMR) Up to Month 18","type":"SECONDARY","unitOfMeasure":"percentage of participants"}